Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

Journal of Hematology & Oncology

Kongming Wu¹  Guoqing Hu¹  Hanxiao Xu¹  Hua Wu¹  Yijun Tian¹  Xun Yuan¹  Wei Sun¹ 

[1] Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Road, Wuhan 430030, Hubei, People’s Republic of China

关键词: Non-small-cell lung cancer;    Circulating tumor cells;    Proteomics;    MicroRNAs;    Circulating cell-free tumor DNA;    Tyrosine kinase inhibitors;    Epidermal growth factor receptor;   

Others  :  1222145
DOI  :  10.1186/s13045-015-0193-6

 received in 2015-06-14, accepted in 2015-07-20,  发布年份 2015

【 摘 要 】

Tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR-TKIs) are standard treatments for advanced non-small-cell lung cancer (NSCLC) patients harboring activating epidermal growth factor receptor (EGFR) mutations. Nowadays, tumor tissues acquired by surgery or biopsy are the routine materials for EGFR mutation analysis. However, the accessibility of tumor tissues is not always satisfactory in advanced NSCLC. Moreover, a high proportion of NSCLC patients will eventually develop resistance to EGFR-TKIs. Invasive procedures, such as surgery or biopsy, are impractical to be performed repeatedly to assess the evolution of EGFR-TKI resistance. Thus, exploring some convenient and less invasive techniques to monitor EGFR-TKI treatment is urgently needed. Circulating cell-free tumor DNA (ctDNA) has a high degree of specificity to detect EGFR mutations in NSCLC. Besides, ctDNA is capable of monitoring the disease progression during EGFR-TKI treatment. Certain serum microRNAs that correlate with EGFR signaling pathway, such as miR-21 and miR-10b, have been demonstrated to be helpful in evaluating the efficiency of EGFR-TKI therapeutics. A commercialized serum-based proteomic test, named VeriStrat test, has shown an outstanding ability to predict the clinical outcome of NSCLC patients receiving EGFR-TKIs. Analysis of EGFR mutations in circulating tumor cells (CTCs) is feasible, and CTCs represent a promising material to predict EGFR-TKI-treatment efficacy and resistance. These evidences suggested that non-invasive techniques based on serum or plasma samples had a great potential for monitoring EGFR-TKI treatment in NSCLC. In this review, we summarized these non-invasive approaches and considered their possible applications in EGFR-TKI-treatment monitoring.

【 授权许可】

   
2015 Sun et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108.
• [2]Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER cancer statistics review, 1975–2012. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015
• [3]Farago AF, Snyder EL, Jacks T. SnapShot: lung cancer models. Cell. 2012; 149(1):246-6.
• [4]Iragavarapu C, Mustafa M, Akinleye A, Furqan M, Mittal V, Cang S et al.. Novel ALK inhibitors in clinical use and development. J Hematol Oncol. 2015; 8(1):17.
• [5]Yuan X, Wu H, Han N, Xu H, Chu Q, Yu S et al.. Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application. J Hematol Oncol. 2014; 7(1):87.
• [6]Yuan X, Wu H, Xu H, Han N, Chu Q, Yu S et al.. Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis. Sci Rep. 2015; 5:10338.
• [7]Parikh K, Cang S, Sekhri A, Liu D. Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents. J Hematol Oncol. 2014; 7:78.
• [8]Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S, Festuccia C. Nucleo-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol. 2014; 7:85.
• [9]Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V et al.. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011; 29(21):2866-2874.
• [10]Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007; 7(3):169-181.
• [11]Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borras AM, Gale CM et al.. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest. 2006; 116(10):2695-2706.
• [12]Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J et al.. Erlotinib in lung cancer - molecular and clinical predictors of outcome. New Engl J Med. 2005; 353(2):133-144.
• [13]Hirsch FR, Varella-Garcia M, Bunn PA, Franklin WA, Dziadziuszko R, Thatcher N et al.. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006; 24(31):5034-5042.
• [14]Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R et al.. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2010; 28(5):744-752.
• [15]Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM et al.. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2011; 29(31):4113-4120.
• [16]Janne PA. Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. Lung Cancer. 2008; 60 Suppl 2:S3-9.
• [17]Niu FY, Wu YL. Novel agents and strategies for overcoming EGFR TKIs resistance. Exp Hematol Oncol. 2014; 3(1):2.
• [18]Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol. 2014; 7(1):70.
• [19]Zhang J, Cao J, Li J, Zhang Y, Chen Z, Peng W et al.. A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors. J Hematol Oncol. 2014; 7:22.
• [20]Overman MJ, Modak J, Kopetz S, Murthy R, Yao JC, Hicks ME et al.. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol. 2013; 31(1):17-22.
• [21]Sun H, Gan ZC, Gao JJ, Zheng F. Non-invasive detection of EGFR deletion at exon 19 in non-small cell lung cancer by real time diagnostic. Clin Lab. 2014; 60(9):1517-1526.
• [22]Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G et al.. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014; 9(9):1345-1353.
• [23]Kim HR, Lee SY, Hyun DS, Lee MK, Lee HK, Choi CM et al.. Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping. J Exp Clin Cancer Res. 2013; 32(1):50.
• [24]Mok T, Wu YL, Lee JS, Yu CJ, Sriuranpong V, Sandoval-Tan J, et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res. 2015 [Epub ahead of print].
• [25]Li B, Ren S, Li X, Wang Y, Garfield D, Zhou S et al.. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer. Lung Cancer. 2014; 83(2):146-153.
• [26]Shen Y, Tang D, Yao R, Wang M, Wang Y, Yao Y et al.. MicroRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation. Med Oncol. 2013; 30(4):750.
• [27]Indovina P, Marcelli E, Maranta P, Tarro G. Lung cancer proteomics: recent advances in biomarker discovery. Int J Proteomics. 2011; 2011:726869.
• [28]Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K et al.. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst. 2007; 99(11):838-846.
• [29]Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H et al.. VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer. 2010; 69(3):337-340.
• [30]Kuiper JL, Lind JS, Groen HJ, Roder J, Grigorieva J, Roder H et al.. VeriStrat((R)) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib. Br J Cancer. 2012; 107(11):1820-1825.
• [31]Gautschi O, Dingemans AM, Crowe S, Peters S, Roder H, Grigorieva J et al.. VeriStrat(R) has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. Lung Cancer. 2013; 79(1):59-64.
• [32]Marchetti A, Del Grammastro M, Felicioni L, Malatesta S, Filice G, Centi I et al.. Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment. PLoS One. 2014; 9(8): Article ID e103883
• [33]Ran R, Li L, Wang M, Wang S, Zheng Z, Lin PP. Determination of EGFR mutations in single cells microdissected from enriched lung tumor cells in peripheral blood. Anal Bioanal Chem. 2013; 405(23):7377-7382.
• [34]Breitenbuecher F, Hoffarth S, Worm K, Cortes-Incio D, Gauler TC, Kohler J et al.. Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients. PLoS One. 2014; 9(1): Article ID e85350
• [35]Nie K, Jia Y, Zhang X. Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer. Tumour Biol. 2015; 36(1):7-19.
• [36]Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM et al.. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013; 497(7447):108-112.
• [37]Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, Hughes BG et al.. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res. 2012; 18(8):2391-2401.
• [38]He C, Liu M, Zhou C, Zhang J, Ouyang M, Zhong N et al.. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int J Cancer. 2009; 125(10):2393-2399.
• [39]Kimura H, Kasahara K, Shibata K, Sone T, Yoshimoto A, Kita T et al.. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer. J Thorac Oncol. 2006; 1(3):260-267.
• [40]Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K et al.. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol. 2012; 7(1):115-121.
• [41]Yung TK, Chan KC, Mok TS, Tong J, To KF, Lo YM. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res. 2009; 15(6):2076-2084.
• [42]Mack PC, Holland WS, Burich RA, Sangha R, Solis LJ, Li Y et al.. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol. 2009; 4(12):1466-1472.
• [43]Jiang B, Liu F, Yang L, Zhang W, Yuan H, Wang J et al.. Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer. J Int Med Res. 2011; 39(4):1392-1401.
• [44]Zhang H, Liu D, Li S, Zheng Y, Yang X, Li X et al.. Comparison of EGFR signaling pathway somatic DNA mutations derived from peripheral blood and corresponding tumor tissue of patients with advanced non-small-cell lung cancer using liquidchip technology. J Mol Diagn. 2013; 15(6):819-826.
• [45]Liu X, Lu Y, Zhu G, Lei Y, Zheng L, Qin H et al.. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies. J Clin Pathol. 2013; 66(12):1065-1069.
• [46]Xu F, Wu J, Xue C, Zhao Y, Jiang W, Lin L et al.. Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. Onco Targets Ther. 2012; 5:439-447.
• [47]Sriram KB, Tan ME, Savarimuthu SM, Wright CM, Relan V, Stockwell RE et al.. Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer. Eur Respir J. 2011; 38(4):903-910.
• [48]Qiu M, Wang J, Xu Y, Ding X, Li M, Jiang F et al.. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2015; 24(1):206-212.
• [49]Luo J, Shen L, Zheng D. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Sci Rep. 2014; 4:6269.
• [50]Weber B, Meldgaard P, Hager H, Wu L, Wei W, Tsai J et al.. Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. BMC Cancer. 2014; 14:294.
• [51]Wood SL, Pernemalm M, Crosbie PA, Whetton AD. Molecular histology of lung cancer: from targets to treatments. Cancer Treat Rev. 2015; 41(4):361-375.
• [52]Del Re M, Vasile E, Falcone A, Danesi R, Petrini I. Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. Expert Rev Mol Diagn. 2014; 14(4):453-468.
• [53]Taniguchi K, Uchida J, Nishino K, Kumagai T, Okuyama T, Okami J et al.. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res. 2011; 17(24):7808-7815.
• [54]Cortinovis D, Monica V, Pietrantonio F, Ceresoli GL, La Spina CM, Wannesson L. MicroRNAs in non-small cell lung cancer: current status and future therapeutic promises. Curr Pharm Des. 2014; 20(24):3982-3990.
• [55]Kim M, Slack FJ. MicroRNA-mediated regulation of KRAS in cancer. J Hematol Oncol. 2014; 7(1):84.
• [56]Chai ZT, Zhu XD, Ao JY, Wang WQ, Gao DM, Kong J et al.. MicroRNA-26a suppresses recruitment of macrophages by down-regulating macrophage colony-stimulating factor expression through the PI3K/Akt pathway in hepatocellular carcinoma. J Hematol Oncol. 2015; 8(1):56.
• [57]Shen H, Zhu F, Liu J, Xu T, Pei D, Wang R et al.. Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer. PLoS One. 2014; 9(7): Article ID e103305
• [58]Wang F, Chan LW, Law HK, Cho WC, Tang P, Yu J et al.. Exploring microRNA-mediated alteration of EGFR signaling pathway in non-small cell lung cancer using an mRNA:miRNA regression model supported by target prediction databases. Genomics. 2014; 104(6):504-511.
• [59]Zhou JY, Chen X, Zhao J, Bao Z, Chen X, Zhang P et al.. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET. Cancer Lett. 2014; 351(2):265-271.
• [60]Ahmad A, Maitah MY, Ginnebaugh KR, Li Y, Bao B, Gadgeel SM et al.. Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs. J Hematol Oncol. 2013; 6(1):77.
• [61]Hou B, Ishinaga H, Midorikawa K, Shah SA, Nakamura S, Hiraku Y et al.. Circulating microRNAs as novel prognosis biomarkers for head and neck squamous cell carcinoma. Cancer Biol Ther. 2015; 16(7):1042-1046.
• [62]Khoury S, Tran N. Circulating microRNAs: potential biomarkers for common malignancies. Biomark Med. 2015; 9(2):131-151.
• [63]Hansen TF, Carlsen AL, Heegaard NH, Sorensen FB, Jakobsen A. Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer. Br J Cancer. 2015; 112(4):624-629.
• [64]Wang WT, Chen YQ. Circulating miRNAs in cancer: from detection to therapy. J Hematol Oncol. 2014; 7(1):86.
• [65]Wang WT, Zhao YN, Yan JX, Weng MY, Wang Y, Chen YQ et al.. Differentially expressed microRNAs in the serum of cervical squamous cell carcinoma patients before and after surgery. J Hematol Oncol. 2014; 7:6.
• [66]Summerer I, Niyazi M, Unger K, Pitea A, Zangen V, Hess J et al.. Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients. Radiat Oncol. 2013; 8:296.
• [67]Jones K, Nourse JP, Keane C, Bhatnagar A, Gandhi MK. Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res. 2014; 20(1):253-264.
• [68]Sallam RM. Proteomics in cancer biomarkers discovery: challenges and applications. Dis Markers. 2015; 2015:321370.
• [69]Tanvetyanon T, Creelan BC, Chiappori AA. Current clinical application of genomic and proteomic profiling in non-small-cell lung cancer. Cancer Control. 2014; 21(1):32-39.
• [70]Akerley W, Boucher K, Rich N, Egbert L, Harker G, Bylund J et al.. A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation. Lung Cancer. 2013; 79(3):307-311.
• [71]Stinchcombe TE, Roder J, Peterman AH, Grigorieva J, Lee CB, Moore DT et al.. A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol. 2013; 8(4):443-451.
• [72]Sun W, Hu G, Long G, Wang J, Liu D, Hu G. Predictive value of a serum-based proteomic test in non-small-cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors: a meta-analysis. Curr Med Res Opin. 2014; 30(10):2033-2039.
• [73]Gregorc V, Novello S, Lazzari C, Barni S, Aieta M, Mencoboni M et al.. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. Lancet Oncol. 2014; 15(7):713-721.
• [74]Lianidou ES, Strati A, Markou A. Circulating tumor cells as promising novel biomarkers in solid cancers. Crit Rev Clin Lab Sci. 2014; 51(3):160-171.
• [75]Tsao DA, Yang MJ, Chang HJ, Yen LC, Chiu HH, Hsueh EJ et al.. A fast and convenient new technique to detect the therapeutic target, K-ras mutant, from peripheral blood in non-small cell lung cancer patients. Lung Cancer. 2010; 68(1):51-57.
• [76]Faugeroux V, Pailler E, Auger N, Taylor M, Farace F. Clinical utility of circulating tumor cells in ALK-positive non-small-cell lung cancer. Front Oncol. 2014; 4:281.
• [77]Pailler E, Adam J, Barthelemy A, Oulhen M, Auger N, Valent A et al.. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol. 2013; 31(18):2273-2281.
• [78]Ilie M, Long E, Butori C, Hofman V, Coelle C, Mauro V et al.. ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. Ann Oncol. 2012; 23(11):2907-2913.
• [79]Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV et al.. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008; 359(4):366-377.
• [80]Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF et al.. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005; 2(3): Article ID e73
• [81]Jian G, Songwen Z, Ling Z, Qinfang D, Jie Z, Liang T et al.. Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2010; 136(9):1341-1347.
• [82]Zhang L, Yang H, Zhao Y, Liu W, Wu S, He J et al.. Detection of EGFR somatic mutations in non-small cell lung cancer (NSCLC) using a novel mutant-enriched liquidchip (MEL) technology. Curr Drug Metab. 2012; 13(7):1007-1011.
• [83]Zhao X, Han RB, Zhao J, Wang J, Yang F, Zhong W et al.. Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients. Respiration. 2013; 85(2):119-125.
• [84]Kim ST, Jung HY, Sung JS, Jo UH, Tanaka T, Hagiwara K et al.. Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer? Am J Clin Oncol. 2013; 36(1):57-63.
• [85]Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT et al.. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol. 2009; 27(16):2653-2659.
• [86]Kuang Y, Rogers A, Yeap BY, Wang L, Makrigiorgos M, Vetrand K et al.. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res. 2009; 15(8):2630-2636.
• [87]Kimura H, Suminoe M, Kasahara K, Sone T, Araya T, Tamori S et al.. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer. 2007; 97(6):778-784.
• [88]Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B et al.. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res. 2006; 12(13):3915-3921.
• [89]Brevet M, Johnson ML, Azzoli CG, Ladanyi M. Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer. 2011; 73(1):96-102.
• [90]Wang S, Han X, Hu X, Wang X, Zhao L, Tang L et al.. Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients. Clin Chim Acta. 2014; 430:63-70.
• [91]Jing CW, Wang Z, Cao HX, Ma R, Wu JZ. High resolution melting analysis for epidermal growth factor receptor mutations in formalin-fixed paraffin-embedded tissue and plasma free DNA from non-small cell lung cancer patients. Asian Pac J Cancer Prev. 2014; 14(11):6619-6623.
• [92]Huang Z, Wang Z, Bai H, Wu M, An T, Zhao J et al.. The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. Thorac Cancer. 2012; 3:334-340.